Compare BAOS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAOS | XRTX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.2M |
| IPO Year | 2020 | 2018 |
| Metric | BAOS | XRTX |
|---|---|---|
| Price | $2.73 | $3.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.3K | ★ 1.8M |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $0.35 |
| 52 Week High | $5.40 | $3.60 |
| Indicator | BAOS | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 73.22 |
| Support Level | $2.60 | $0.52 |
| Resistance Level | $2.82 | N/A |
| Average True Range (ATR) | 0.20 | 0.38 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 76.14 | 62.58 |
Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.